Clinical Outcomes of Patients with EGFR T790M+NSCLC on Osimertinib

被引：0
|
作者：
Tan, W. L. [1 ]
Hennedige, T. P. [2 ]
Ng, Q. S. [3 ]
Tan, S. H. [4 ]
Tran, N. T. A. [5 ]
Chua, B. J. G. [6 ]
Toh, C. K. [3 ]
Tan, E. H. [3 ]
Tan, D. [3 ]
Ang, M. [3 ]
Kanesvaran, R. [3 ]
Jain, A. [3 ]
Lim, T. K. H. [7 ]
Gogna, A. [8 ]
Koh, M. [9 ]
Yip, C. S. P. [10 ]
Thng, C. H. [2 ]
Chowbay, B. [11 ]
Tan, M. H. [3 ]
Lim, W. [3 ]
机构：
[1] Natl Canc Ctr Singapore, Med Oncol, Singapore, Singapore
[2] Natl Canc Ctr Singapore, Oncol Imaging, Singapore, Singapore
[3] Natl Canc Ctr, Med Oncol, Singapore, Singapore
[4] Natl Canc Ctr Singapore, Clin Trial Off, Singapore, Singapore
[5] Moh Holdings, Diagnost Radiol, Singapore, Singapore
[6] Moh Holdings, Singapore, Singapore
[7] Singhealth, Anat Pathol, Singapore, Singapore
[8] Singhealth, Diagnost Radiol, Singapore, Singapore
[9] Singhealth, Pulmonol, Singapore, Singapore
[10] Natl Canc Ctr Singapore, Radiat Oncol, Singapore, Singapore
[11] Natl Canc Ctr Singapore, Med Sci & Clin Pharmacol, Singapore, Singapore
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
EGFR T790M; osimertinib; NSCLC;
D O I：
10.1016/j.jtho.2017.09.1458
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.01-017
引用
收藏
页码：S2206 / S2206
页数：1
相关论文
共 50 条
  • [41] ASTRIS: A Real World Study of Osimertinib Treatment in Patients with EGFR T790M Positive Advanced NSCLC; Interim Analysis
    Kim, S.
    Cho, B. C.
    Kim, D.
    Park, K.
    Tiseo, M.
    Migliorino, M. R.
    Santo, A.
    Lee, J.
    Vicente, D.
    Paredes, A.
    O'Hanrahan, E.
    Freitas, H.
    Provencio, M.
    Chen, Y.
    Cheema, P.
    Milner, A.
    Rigas, J.
    Wu, Y.
    De Marinis, F.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2202 - S2202
  • [42] Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes
    Cortellini, A.
    Leonetti, A.
    Catino, A.
    Pizzutillo, P.
    Ricciuti, B.
    De Giglio, A.
    Chiari, R.
    Bordi, P.
    Santini, D.
    Giusti, R.
    De Tursi, M.
    Brocco, D.
    Zoratto, F.
    Rastelli, F.
    Citarella, F.
    Russano, M.
    Filetti, M.
    Marchetti, P.
    Berardi, R.
    Torniai, M.
    Cortinovis, D.
    Sala, E.
    Maggioni, C.
    Follador, A.
    Macerelli, M.
    Nigro, O.
    Tuzi, A.
    Iacono, D.
    Migliorino, M. R.
    Banna, G.
    Porzio, G.
    Cannita, K.
    Ferrara, M. G.
    Bria, E.
    Galetta, D.
    Ficorella, C.
    Tiseo, M.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (06): : 844 - 851
  • [43] Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study
    Cao, Y.
    Qiu, X.
    Xiao, G.
    Hao, H.
    ANNALS OF ONCOLOGY, 2017, 28
  • [44] Osimertinib Expanded Access Program for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC
    Santos, Edgardo
    Kaplan, Barry
    Kirshner, Eli
    Croft, Elisabeth
    Sequist, Lecia
    Burke, Lea
    Munley, Jiefen
    Oxnard, Geoffrey
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1237 - S1237
  • [45] Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis
    Ahn, Myung-Ju
    Chiu, Chao-Hua
    Cheng, Ying
    Han, Ji-Youn
    Goldberg, Sarah B.
    Greystoke, Alastair
    Crawford, Jeffrey
    Zhao, Yanqiu
    Huang, Xiangning
    Johnson, Martin
    Vishwanathan, Karthick
    Yates, James W. T.
    Brown, Andrew P.
    Mendoza-Naranjo, Ariadna
    Mok, Tony
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (04) : 637 - 648
  • [46] Clinical features and progression pattern of T790M+compared with T790M-EGFR mutant NSCLC.
    Pasello, Giulia
    Dal Maso, Alessandro
    Lorenzi, Martina
    Roca, Elisa
    Pilotto, Sara
    Macerelli, Marianna
    Polo, Valentina
    Del Conte, Alessandro
    Nardo, Giorgia
    Buoro, Vanessa
    Scattolin, Daniela
    Monteverdi, Sara
    Urso, Loredana
    Zulato, Elisabetta
    Frega, Stefano
    Bonanno, Laura
    Indraccolo, Stefano
    Calabrese, Fiorella
    Conte, Pierfranco
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [47] Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
    Papadimitrakopoulou, V. A.
    Wu, Y-L.
    Han, J-Y.
    Ahn, M-J.
    Ramalingam, S. S.
    John, T.
    Okamoto, I.
    Yang, J. C-H.
    Bulusu, K. C.
    Laus, G.
    Collins, B.
    Barrett, J. C.
    Chmielecki, J.
    Mok, T. S. K.
    ANNALS OF ONCOLOGY, 2018, 29 : 741 - 741
  • [48] Real-World Safety and Efficacy Data of Osimertinib in Patients from Japan with EGFR T790M-Positive NSCLC
    Ohe, Y.
    Kato, T.
    Shimizu, W.
    Sakamoto, K.
    Sugeno, M.
    Tamura, R.
    Tokimoto, T.
    Gemma, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S852 - S852
  • [49] Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes
    A. Cortellini
    A. Leonetti
    A. Catino
    P. Pizzutillo
    B. Ricciuti
    A. De Giglio
    R. Chiari
    P. Bordi
    D. Santini
    R. Giusti
    M. De Tursi
    D. Brocco
    F. Zoratto
    F. Rastelli
    F. Citarella
    M. Russano
    M. Filetti
    P. Marchetti
    R. Berardi
    M. Torniai
    D. Cortinovis
    E. Sala
    C. Maggioni
    A. Follador
    M. Macerelli
    O. Nigro
    A. Tuzi
    D. Iacono
    M. R. Migliorino
    G. Banna
    G. Porzio
    K. Cannita
    M. G. Ferrara
    E. Bria
    D. Galetta
    C. Ficorella
    M. Tiseo
    Clinical and Translational Oncology, 2020, 22 : 844 - 851
  • [50] Effectiveness and safety of osimertinib in patients with metastatic EGFR T790M-positive NSCLC: An observational real-world study
    Cao, Yabing
    Qiu, Xibin
    Xiao, Guangli
    Hu, Hao
    Lin, Tongyu
    PLOS ONE, 2019, 14 (08):
12345